The sensitivity of MYCN amplification to poly (ADP-ribose) polymerase 1 (PARP1) inhibition in neuroblastoma [110] and the identification of the MYCN-PARP1/2-DNA damage repair (DDR) pathway as a driver of transition to NEPC provide the rationale for combining AURKA inhibitors with PARP1 inhibitors. This evidence concerns the gene PARP1 and neuroblastoma.